Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Kura Oncology's 15% one-day jump is pure ticker confusion, making it the cleanest fade on the tape if puts are liquid. Trump's Q1 disclosure showed $1-5M in "Kura," meaning Kura Sushi USA, but retail bought Kura Oncology, an unrelated clinical-stage cancer biotech now at a $917M market cap. The intended buy may even have been Fujikura, a Japanese fiber-optic supplier. Options activity is extreme for a thinly traded stock, with a 0.007 put/call ratio and no fundamental anchor. x.com